FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 666 FIFTH AVENUE. 31ST FLOOR NEW YORK, NEW YORK 10103-3198 WWW.FULBRIGHT.COM

FACSIMILE TRANSMISSION

DATE: F

February 13, 2003

MATTER NUMBER:

10103726

RECIPIENT(s):	FAX No.:	PHONE No.:
Examiner Sandra Saucier	703-308-2742	
USPTO, Group 1651		

FAX RECEIVED
FEB 1 4 2003
GROUP 1600

Norman Hanson (212) 318-3168

USER ID:

NH01030

FLOOR:

FAX:

(212) 318-3400

PHONE: Re:

NIAD 213.1

Number of Pages with Cover Page: 4

Message:	 <u> </u>	
		:

CAUTION - CONFIDENTIAL

THE INFORMATION CONTAINED IN THIS FACEIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY POR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY USE DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THE FACSIMILE IN ERROR, PLEASE DIMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA THIS U.S. POSTAL SERVICE, THANK YOU.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL
____AT ____AS SOON AS POSSIBLE.

TO 0103010103726170 P.02/

NIAD 213.1 (10103726)- NDH

VIA FACSIMILE

I hereby certify that this correspondence is being facsimile transmitted to the Commissioner of Patents and Trademarks, Washington, D.C. 20231 on February 13, 2003.

Fulbright & Jaworski L.L.P.

Olly

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applicant

Jacobson, et al.

Serial No.

09/836,576

Filed

April 16, 2001

For

METHODS FOR IDENTIFYING REGULATORS OF

PROTEIN-ADVANCED GLYCATION END PRODUCT

(PROTEIN-AGE) FORMATION

Art Unit

1651

Examiner

S. Saucier

February 13 2003

Hon. Commissioner of Patents and Trademarks Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT

This is in response to the restriction requirement of February 5. The examiner required restriction between method claims 1-10, and kit claim 11.

Applicants elect Group I, claims 1-10, with traverse.

The examiner argues that the kit of Group II is not required to carry out the assay, and kits have structure not required in the carrying out of the assay.

Applicants respond by noting that the examiner has not pointed to any other use for the kit of claim 11 other than for use in the assay of claims 1-10. With respect to the examiner's point regarding "multiple methods," this is obscure. The relevance to the invention is not seen. In any event, since the claimed subject matter, i.e., claims 1-10, requires both histone H1 and

25262R36.1